Nerve damage in leprosy: A continuing challenge to scientists, clinicians and service providers

International Health

Volumn 4, Issue 2, 2012, Pages 77-85

  Lockwood, Diana N ^a   Saunderson, Paul R ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b American Leprosy Missions   (United States)

Author keywords

Inflammation; Leprosy; Leprosy reactions; Neuropathic pain; Peripheral neuropathy; Steroid treatment

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; STEROID;

ANTIBIOTIC THERAPY; CHRONIC DISEASE; HUMAN; LEPROSY; MYCOBACTERIUM LEPRAE; NEURITIS; NEUROPATHIC PAIN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; REVIEW; SKIN NERVE; STEROID THERAPY; T LYMPHOCYTE; TREATMENT DURATION;

EID: 84861698347     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1016/j.inhe.2011.09.006     Document Type: Review

References (51)

1. Britton W.J., Lockwood D.N. Leprosy. Lancet 2004, 363:1209-1219.
2. Scollard D.M., Adams L.B., Gillis T.P., Krahenbuhl J.L., Truman R.W., Williams D.L. The continuing challenges of leprosy. Clin Microbiol Rev 2006, 19:338-381.
3. WHO Global leprosy situation, 2009. Wkly Epidemiol Rec 2009, 84:333-340.
4. Croft R.P., Nicholls P.G., Steyerberg E.W., Richardus J.H., Cairns W., Smith S. A clinical prediction rule for nerve-function impairment in leprosy patients. Lancet 2000, 355:1603-1606.
5. Saunderson P., Gebre S., Desta K., Byass P., Lockwood D.N. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000, 71:285-308.
6. van Brakel W.H., Nicholls P.G., Das L., et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev 2005, 76:14-34.
7. Van Veen N.H., Meima A., Richardus J.H. The relationship between detection delay and impairment in leprosy control: a comparison of patient cohorts from Bangladesh and Ethiopia. Lepr Rev 2006, 77:356-365.
8. Bekri W., Gebre S., Mengiste A., Saunderson P.R., Zewge S. Delay in presentation and start of treatment in leprosy patients: a case-control study of disabled and non-disabled patients in three different settings in Ethiopia. Int J Lepr Other Mycobact Dis 1998, 66:1-9.
9. Meima A., Saunderson P.R., Gebre S., et al. Factors associated with impairments in new leprosy patients: the AMFES cohort. Lepr Rev 1999, 70:189-203.
10. Scollard D.M. The biology of nerve injury in leprosy. Lepr Rev 2008, 79:242-253.
11. Shetty V.P. Pathomechanisms of nerve damage. IAL Textbook of leprosy 2010, 237-247. Jaypee Brothers Medical Publishers Ltd, New Delhi. 1st ed. H.K.K.B. Kumar (Ed.).
12. Krutzik S.R., Ochoa M.T., Sieling P.A., et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003, 9:525-532.
13. Oliveira R.B., Ochoa M.T., Sieling P.A., et al. Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy. Infect Immun 2003, 71:1427-1433.
14. Harboe M., Aseffa A., Leekassa R. Challenges presented by nerve damage in leprosy. Lepr Rev 2005, 76:5-13.
15. Shetty V.P., Suchitra K., Uplekar M.W., Antia N.H. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients. Lepr Rev 1992, 63:329-336.
16. Lockwood D.N., Colston M.J., Khanolkar-Young S.R. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 2002, 66:409-415.
17. Khanolkar-Young S., Rayment N., Brickell P.M., et al. Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995, 99:196-202.
18. Lockwood D.N.J., Suneetha L., Sagili K.D., et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis 2011, 5:e1327.
19. Jadhav R., Suneetha L., Kamble R., et al. Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India. PLoS Negl Trop Dis 2011, 5:e977.
20. Save M.P., Shetty V.P., Shetty K.T. Hypophosphorylation of NF-H and NF-M subunits of neurofilaments and the associated decrease in KSPXK kinase activity in the sciatic nerves of swiss white mice inoculated in the foot pad with Mycobacterium leprae. Lepr Rev 2009, 80:388-401.
21. Save M.P., Shetty V.P., Shetty K.T., Antia N.H. Alterations in neurofilament protein(s) in human leprous nerves: morphology, immunohistochemistry and Western immunoblot correlative study. Neuropathol Appl Neurobiol 2004, 30:635-650.
22. Job C.K. Pathology of peripheral nerve lesions in lepromatous leprosy-a light and electron microscopic study. Int J Lepr Other Mycobact Dis 1971, 39:251-268.
23. Shetty V.P., Antia N.H. Nerve damage in leprosy. Int J Lepr Other Mycobact Dis 1988, 56:619-621.
24. Bochud P.Y., Hawn T.R., Siddiqui M.R., et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008, 197:253-261.
25. Little D., Khanolkar-Young S., Coulthart A., Suneetha S., Lockwood DN Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 2001, 69:3413-3417.
26. Rambukkana A., Zanazzi G., Tapinos N., Salzer J.L. Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells. Science 2002, 296:927-931.
27. Deps P., Lockwood D.N. Leprosy presenting as immune reconstitution inflammatory syndrome: proposed definitions and classification. Lepr Rev 2010, 81:59-68.
28. Lawn S.D., Lockwood D.N. Leprosy after starting antiretroviral treatment. BMJ 2007, 334:217-218.
29. Bell-Krotoski J., Tomancik E. The repeatability of testing with Semmes-Weinstein monofilaments. J Hand Surg Am 1987, 12:155-161.
30. van Brakel W.H., Nicholls P.G., Wilder-Smith E.P., et al. Early diagnosis of neuropathy in leprosy-comparing diagnostic tests in a large prospective study (the INFIR Cohort Study). PLoS Negl Trop Dis 2008, 2:e212.
31. Smith W.C., Nicholls P.G., Das L., et al. Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study. PLoS Negl Trop Dis 2009, 3:e500.
32. Van Veen N.H., Nicholls P.G., Smith W.C., Richardus J.H. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev 2007, 2. CD005491.
33. Walker S.L., Lockwood D.N. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 2008, 79:372-386.
34. Rao P.S., Sugamaran D.S., Richard J., Smith W.C. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006, 77:25-33.
35. Walker S.L., Nicholls P.G., Dhakal S., et al. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl Trop Dis 2011, 5:e1041.
36. Marlowe S.N., Hawksworth R.A., Butlin C.R., Nicholls P.G., Lockwood D.N. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg 2004, 98:602-609.
37. Marlowe S.N., Leekassa R., Bizuneh E., et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg 2007, 101:1004-1012.
38. Croft R.P., Nicholls P.G., Richardus J.H., Smith W.C. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev 2000, 71:154-168.
39. Smith W.C., Anderson A.M., Withington S.G., et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 2004, 328:1459.
40. Saunderson P., Bizuneh E., Leekassa R. Neuropathic pain in people treated for multibacillary leprosy more than ten years previously. Lepr Rev 2008, 79:270-276.
41. Lasry-Levy E., Hietaharju A., Pai V., et al. Neuropathic pain and psychological morbidity in patients with treated leprosy: a cross-sectional prevalence study in Mumbai. PLoS Negl Trop Dis 2011, 5:e981.
42. Lund C., Koskinen M., Suneetha S., et al. Histopathological and clinical findings in leprosy patients with chronic neuropathic pain: a study from Hyderabad, India. Lepr Rev 2007, 78:369-380.
43. Saunderson P. Learning to manage leprosy after 2005: preserving critical knowledge and exploiting new technology. Lepr Rev 2005, 76:2-4.
44. Shetty V.P., Thakar U.H., D'Souza E., et al. Detection of previously undetected leprosy cases in a defined rural and urban area of Maharashtra, Western India. Lepr Rev 2009, 80:22-33.
45. Benbow C., Tamiru T. The experience of self-care groups with people affected by leprosy: ALERT, Ethiopia. Lepr Rev 2001, 72:311-321.
46. Post E. Field treatment of leprosy reactions in Northern Nigeria: feasibility, including the use of prednisolone in blister packs. Lepr Rev 2003, 74:259-262.
47. Duthie M.S., Hay M.N., Morales C.Z., et al. Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis. Clin Vaccine Immunol 2010, 17:298-303.
48. Geluk A., van der Ploeg-van Schip J.J., van Meijgaarden K.E., et al. 2010 Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays. Clin Vaccine Immunol 2010, 17:993-1004.
49. Garbino J.A., Virmond Mda C., Ura S., Salgado M.H., Naafs B. A randomized clinical trial of oral steroids for ulnar neuropathy in type 1 and type 2 leprosy reactions. Arq Neuropsiquiatr 2008, 66:861-867.
50. Richardus J.H., Withington S.G., Anderson A.M., et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev 2003, 74:311-318.
51. Van Brakel W.H., Anderson A.M., Withington S.G., et al. The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev 2003, 74:300-310.